Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication
- Fevipiprant was well tolerated with adverse events balanced across treatment groups
# # #
Novartis Media Relations Central media line: +41 61 324 2200 E-mail:?media.relations@novartis.comPeter Z?st Novartis Global External Communications +41 79 899 9812 (mobile) peter.zuest@novartis.com Eric Althoff Novartis US External Communications +1 646 438 4335 eric.althoff@novartis.com | Phil McNamara Global Head, Respiratory Communications +1 862 274 5255 (mobile) philip.mcnamara@novartis.com |
Central | North America | ||
Samir Shah | +41 61 324 7944 | Richard Pulik | +1 862 778 3275 |
Pierre-Michel Bringer | +41 61 324 1065 | Cory Twining | +1 862 778 3258 |
Thomas Hungerbuehler | +41 61 324 8425 | ||
Isabella Zinck | +41 61 324 7188 |